Meeting News

Patients maintain scalp psoriasis clearance with higher doses of mirikizumab

Clearance of scalp psoriasis was maintained at 52 weeks with higher doses of mirikizumab, a humanized monoclonal antibody, according to study data presented at the World Congress of Dermatology.

In a phase 2 study, 52 patients with moderate to severe scalp psoriasis were randomly assigned to receive placebo, and 51 patients were assigned to each mirikizumab (Eli Lilly) treatment group of 30 mg, 100 mg or 300 mg.

Patients who did not achieve an improvement of 90% or more in Psoriasis Area Severity Index (PASI 90) at week 16 received mirikizumab 300 mg every 8 weeks, encompassing the maintenance dosing period.

The proportion of patients that did not achieve PASI 90 at week 16 improved by week 52 following maintenance dosing. From weeks 16 to 52, of the 46 patients who transitioned from placebo to maintenance dosing, Psoriasis Scalp Severity Index (PSSI) score of 0, denoting complete scalp psoriasis clearance, increased from 6.5% to 80.4%. In the 30-mg group, 31 patients received maintenance dosing, and PSSI score of 0 increased from 35.3% to 67.7%. In the 100-mg group, 21 patients received maintenance dosing, and PSSI score of 0 increased from 47.6% to 76.2%, and for the 15 patients in the 300-mg group transitioned to maintenance dosing, PSSI score of 0 increased from 13.3% to 66.7%.

The mean PSSI score change from baseline in placebo to mirikizumab 300 mg every 8 weeks was 10.5 at week 16 and 97.6 at week 52; from 30 mg to 300 mg every 8 weeks, 72 at week 16 and 94.3 at week 52; from 100 mg to 300 mg every 8 weeks, 89.6 at week 16 to 94.5 at week 52; and from 300 mg to 300 mg every 8 weeks, 35.4 at week 16 to 95.3 at week 52.

 

Reference:

Rich P, et al. Improvement in Psoriasis Scalp Severity Index during maintenance treatment with mirikizumab. Presented at: 24th World Congress of Dermatology; June 10-15, 2019; Milan.

 

Disclosures: Patel is employed by Eli Lilly and Company which sponsored the study.

Clearance of scalp psoriasis was maintained at 52 weeks with higher doses of mirikizumab, a humanized monoclonal antibody, according to study data presented at the World Congress of Dermatology.

In a phase 2 study, 52 patients with moderate to severe scalp psoriasis were randomly assigned to receive placebo, and 51 patients were assigned to each mirikizumab (Eli Lilly) treatment group of 30 mg, 100 mg or 300 mg.

Patients who did not achieve an improvement of 90% or more in Psoriasis Area Severity Index (PASI 90) at week 16 received mirikizumab 300 mg every 8 weeks, encompassing the maintenance dosing period.

The proportion of patients that did not achieve PASI 90 at week 16 improved by week 52 following maintenance dosing. From weeks 16 to 52, of the 46 patients who transitioned from placebo to maintenance dosing, Psoriasis Scalp Severity Index (PSSI) score of 0, denoting complete scalp psoriasis clearance, increased from 6.5% to 80.4%. In the 30-mg group, 31 patients received maintenance dosing, and PSSI score of 0 increased from 35.3% to 67.7%. In the 100-mg group, 21 patients received maintenance dosing, and PSSI score of 0 increased from 47.6% to 76.2%, and for the 15 patients in the 300-mg group transitioned to maintenance dosing, PSSI score of 0 increased from 13.3% to 66.7%.

The mean PSSI score change from baseline in placebo to mirikizumab 300 mg every 8 weeks was 10.5 at week 16 and 97.6 at week 52; from 30 mg to 300 mg every 8 weeks, 72 at week 16 and 94.3 at week 52; from 100 mg to 300 mg every 8 weeks, 89.6 at week 16 to 94.5 at week 52; and from 300 mg to 300 mg every 8 weeks, 35.4 at week 16 to 95.3 at week 52.

 

Reference:

Rich P, et al. Improvement in Psoriasis Scalp Severity Index during maintenance treatment with mirikizumab. Presented at: 24th World Congress of Dermatology; June 10-15, 2019; Milan.

 

Disclosures: Patel is employed by Eli Lilly and Company which sponsored the study.